Literature DB >> 6233162

High affinity binding of [3H]paroxetine and [3H]imipramine to human platelet membranes.

E T Mellerup, P Plenge, M Engelstoft.   

Abstract

Paroxetine, one of the most potent and specific serotonin uptake inhibitors, was tritiated and used for binding studies with human platelet membranes. Specific, high affinity binding was demonstrated. The binding was compared with [3H]imipramine binding; it was found that the maximal binding (Bmax) was the same for [3H]paroxetine and [3H]imipramine, whereas the affinity was much higher for [3H]paroxetine (KD 0.08 nM and 0.56 nM for paroxetine and imipramine binding, respectively). IC50 was calculated for the inhibition of [3H]paroxetine and [3H]imipramine binding by a number of antidepressants; the corresponding Hill coefficients were also calculated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6233162     DOI: 10.1016/0014-2999(83)90321-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  16 in total

1.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Impaired platelet [3H]paroxetine binding in female patients with borderline personality disorder.

Authors:  N M K Ng Ying Kin; Joel Paris; George Schwartz; Hallie Zweig-Frank; Howard Steiger; N P V Nair
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 3.  Studies on the serotonin transporter in platelets.

Authors:  S Z Langer; A M Galzin
Journal:  Experientia       Date:  1988-02-15

4.  Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor.

Authors:  D R Thomas; D R Nelson; A M Johnson
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Platelet 5-HT uptake sites, labelled with [3H] paroxetine, in controls and depressed patients before and after treatment with fluoxetine or lofepramine.

Authors:  K M Lawrence; C L Katona; M T Abou-Saleh; M M Robertson; B L Nairac; D R Edwards; T Lock; R A Burns; D A Harrison; R W Horton
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

6.  Platelet 5-HT uptake sites in depression: three concurrent measures using [3H] imipramine and [3H] paroxetine.

Authors:  K M Lawrence; J Falkowski; R R Jacobson; R W Horton
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Comparative study of platelet 3H-paroxetine and 3H-imipramine binding in panic disorder patients and healthy controls.

Authors:  G Faludi; K Tekes; L Tóthfalusi
Journal:  J Psychiatry Neurosci       Date:  1994-03       Impact factor: 6.186

8.  Solubilization and characterization of [3H]imipramine and [3H]paroxetine binding sites from calf striatum.

Authors:  A Rotondo; G Giannaccini; C Quattrone; D Marazziti; C Martini; G B Cassano; A Lucacchini
Journal:  Neurochem Res       Date:  1994-10       Impact factor: 3.996

9.  Regional studies of serotonin and dopamine metabolism and quantification of serotonin uptake sites in human cerebral cortex.

Authors:  B Parsons; A Roxas; Y Y Huang; A Dwork; M Stanley
Journal:  J Neural Transm Gen Sect       Date:  1992

10.  Catecholamine and MHPG plasma levels, platelet MAO activity, and 3H-imipramine binding in heroin and cocaine addicts.

Authors:  T Macedo; C A Ribeiro; D Cotrim; P Tavares; M T Morgadinho; M Caramona; M T Vicente; L Rodrigues; M G Cardoso; M L Keating
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.